1932

Abstract

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited myocardial disorder, transformed over the last several years into a treatable condition with the emergence of effective management options that alter natural history at all ages. Now available are a matured risk stratification algorithm selecting patients for prophylactic implantable defibrillators that prevent arrhythmic sudden death; low-risk, high-benefit surgical myectomy to reverse progressive heart failure symptoms due to left ventricular outflow obstruction; anticoagulation prophylaxis to prevent atrial fibrillation–mediated embolic stroke; and heart transplant for refractory end-stage disease in the absence of obstruction. Those strategies have resulted in reduction of HCM-related morbidity and reduction of mortality to 0.5% per year.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042220-021539
2022-01-27
2024-06-13
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042220-021539.html?itemId=/content/journals/10.1146/annurev-med-042220-021539&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Maron BJ. 2018. Clinical course and management of hypertrophic cardiomyopathy. N. Engl. J. Med. 379:655–68
    [Google Scholar]
  2. 2. 
    Maron BJ, Rowin EJ, Maron MS. 2018. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail 6:376–78
    [Google Scholar]
  3. 3. 
    Elliott PM, Anastasakis A, Borger MA et al. 2014. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35:2733–79
    [Google Scholar]
  4. 4. 
    Gersh BJ, Maron BJ, Bonow RO et al. 2011. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. Circulation 124:2761–96
    [Google Scholar]
  5. 5. 
    Ommen SR, Mital S, Burke MA et al. 2020. AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 76:e159–e240
    [Google Scholar]
  6. 6. 
    Rowin EJ, Maron MS, Chan RH et al. 2017. Interaction of adverse disease-related pathways in hypertrophic cardiomyopathy. Am. J. Cardiol. 120:2256–64
    [Google Scholar]
  7. 7. 
    Rowin EJ, Maron BJ, Haas TS et al. 2017. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J. Am. Coll. Cardiol. 69:761–73
    [Google Scholar]
  8. 8. 
    Rowin EJ, Maron BJ, Maron MS. 2020. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging: clinical and etiologic implications. JACC Cardiovasc. Imaging 13:2002–16
    [Google Scholar]
  9. 9. 
    Maron BJ, Maron MS, Rowin EJ. 2017. Perspectives on the overall risks of living with hypertrophic cardiomyopathy. Circulation 135:2317–19
    [Google Scholar]
  10. 10. 
    Maron MS, Rowin EJ, Wessler BS et al. 2019. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high risk patients with hypertrophic cardiomyopathy. JAMA Cardiol 4:644–57
    [Google Scholar]
  11. 11. 
    Maron BJ, Rowin EJ, Maron MS. 2021. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: twenty years with the implantable cardioverter-defibrillator. Heart Rhythm 18:1012–23
    [Google Scholar]
  12. 12. 
    Maron BJ, Spirito P, Shen WK et al. 2007. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298:405–12
    [Google Scholar]
  13. 13. 
    Maron BJ, Rowin EJ, Casey SA, Maron MS 2016. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol 1:98–105
    [Google Scholar]
  14. 14. 
    Maron BJ, Casey SA, Olivotto I et al. 2018. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ. Arrhythm. Electrophysiol. 11:e005820
    [Google Scholar]
  15. 15. 
    Kotkar KD, Said SM, Dearani JA, Schaff HV. 2017. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann. Cardiothorac. Surg. 6:329–36
    [Google Scholar]
  16. 16. 
    Wells S, Rowin EJ, Bhatt V et al. 2018. Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. Circulation 137:1973–75
    [Google Scholar]
  17. 17. 
    Eberly LA, Day SM, Ashley EA et al. 2019. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol 5:83–91
    [Google Scholar]
  18. 18. 
    Maron BJ, Casey SA, Poliac LC et al. 1999. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650–55
    [Google Scholar]
  19. 19. 
    Maron BJ, Gardin JM, Flack JM et al. 1995. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92:785–89
    [Google Scholar]
  20. 20. 
    Semsarian C, Ingles J, Maron MS, Maron BJ. 2015. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65:1249–54
    [Google Scholar]
  21. 21. 
    Maron MS, Hellawell JL, Lucove JC et al. 2016. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am. J. Cardiol. 117:1651–54
    [Google Scholar]
  22. 22. 
    Cirino AL, Harris S, Lakdawala NK et al. 2017. Role of genetic testing in inherited cardiovascular disease: a review. JAMA Cardiol 2:1153–60
    [Google Scholar]
  23. 23. 
    Burke MA, Cook SA, Seidman JG, Seidman CE. 2016. Clinical and mechanistic insights into the genetics of cardiomyopathy. J. Am. Coll. Cardiol. 68:2871–86
    [Google Scholar]
  24. 24. 
    Maron BJ, Maron MS, Semsarian C. 2012. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J. Am. Coll. Cardiol. 60:705–15
    [Google Scholar]
  25. 25. 
    Maron BJ, Maron MS, Maron BA, Loscalzo J. 2019. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 73:1978–86
    [Google Scholar]
  26. 26. 
    Toepfer CN, Wakimoto H, Garfinkel AC et al. 2019. Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Sci. Transl. Med. 11:476eaat1199
    [Google Scholar]
  27. 27. 
    Toepfer CN, Garfinkel AC, Venturini G et al. 2020. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 141:828–42
    [Google Scholar]
  28. 28. 
    Maron BJ, Maron MS, Maurer MS et al. 2021. Cardiovascular diseases that have emerged from the darkness. J. Am. Heart Assoc. 10:e021095
    [Google Scholar]
  29. 29. 
    Maron BJ, Rowin EJ, Maron MS. 2020. Hypertrophic cardiomyopathy: Is a “cure” coming…or is it already here?. Am. J. Med. 133:886–88
    [Google Scholar]
  30. 30. 
    Maron BA, Wang RS, Shevtsov S et al. 2021. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat. Commun. 12:873
    [Google Scholar]
  31. 31. 
    Rowin EJ, Maron BJ, Chokshi A et al. 2018. Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy. Am. J. Cardiol. 122:1409–20
    [Google Scholar]
  32. 32. 
    Chan RH, Maron BJ, Olivotto I et al. 2014. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–95
    [Google Scholar]
  33. 33. 
    Rowin EJ, Maron BJ, Carrick RT et al. 2020. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 75:3033–43
    [Google Scholar]
  34. 34. 
    Vriesendorp PA, Schinkel AF, Van Cleemput J et al. 2013. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am. Heart J. 166:496–502
    [Google Scholar]
  35. 35. 
    Schinkel AF, Vriesendorp PA, Sijbrands EJ et al. 2012. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ. Heart Fail. 5:552–59
    [Google Scholar]
  36. 36. 
    Maron BJ, Rowin EJ, Casey SA et al. 2015. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J. Am. Coll. Cardiol. 65:1915–28
    [Google Scholar]
  37. 37. 
    Maron BJ, Rowin EJ, Casey SA et al. 2016. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation 133:62–73
    [Google Scholar]
  38. 38. 
    Maron BJ, Rowin EJ, Maron MS. 2019. Paradigm of sudden death prevention in hypertrophic cardiomyopathy. Circ. Res. 125:370–78
    [Google Scholar]
  39. 39. 
    Rowin EJ, Burrows A, Madias C et al. 2020. Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants. Circ. Arrhythm. Electrophysiol. 13:e008123
    [Google Scholar]
  40. 40. 
    Maron MS, Brush J, Rowin EJ, Maron BJ 2021. Back to the future: predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm 18:148–50
    [Google Scholar]
  41. 41. 
    Maron BJ, Rowin EJ, Casey SA et al. 2013. Risk stratification and outcome of patients with hypertrophic cardiomyopathy ≥60 years of age. Circulation 127:585–93
    [Google Scholar]
  42. 42. 
    O'Mahony C, Jichi F, Ommen SR et al. 2018. International external validation study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). Circulation 137:1015–23
    [Google Scholar]
  43. 43. 
    Lambiase PD, Gold MR, Hood M et al. 2016. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm 13:1066–74
    [Google Scholar]
  44. 44. 
    Maron BJ, Estes NAM. 2021. The “Guidant Affair”: 15 years later. Heart Rhythm 18:487–88
    [Google Scholar]
  45. 45. 
    Maron BJ, Haas TS, Ahluwalia A et al. 2016. Demographics and epidemiology of sudden deaths in young competitive athletes: from the United States National Registry. Am. J. Med. 129:1170–77
    [Google Scholar]
  46. 46. 
    Maron BJ, Udelson JE, Bonow RO et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. J. Am. Coll. Cardiol. 66:2362–71
    [Google Scholar]
  47. 47. 
    Maron BJ. 2015. Historical perspectives on sudden deaths in young athletes with evolution over 35 years. Am. J. Cardiol. 116:1461–68
    [Google Scholar]
  48. 48. 
    Maron BJ. 2003. Sudden death in young athletes. N. Eng. J. Med. 349:1064–75
    [Google Scholar]
  49. 49. 
    Maron MS, Olivotto I, Zenovich AG et al. 2006. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232–39
    [Google Scholar]
  50. 50. 
    Ommen SR, Maron BJ, Olivotto I et al. 2005. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 46:470–76
    [Google Scholar]
  51. 51. 
    Rastegar H, Boll G, Rowin EJ et al. 2017. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann. Cardiothorac. Surg. 6:353–63
    [Google Scholar]
  52. 52. 
    Desai MY, Bhonsale A, Smedira NG et al. 2013. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 128:209–16
    [Google Scholar]
  53. 53. 
    Vanderlaan RD, Woo A, Ralph-Edwards A. 2017. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience. Ann. Cardiothorac. Surg. 6:364–68
    [Google Scholar]
  54. 54. 
    Hodges K, Rivas CG, Aguilera J et al. 2019. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J. Cardiovasc. Surg. 157:2289–99
    [Google Scholar]
  55. 55. 
    Ferrazzi P, Spirito P, Iacovoni A et al. 2015. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J. Am. Coll. Cardiol. 66:1687–96
    [Google Scholar]
  56. 56. 
    Maron BJ, Dearani JA, Ommen SR et al. 2015. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J. Am. Coll. Cardiol. 66:1307–8
    [Google Scholar]
  57. 57. 
    Vriesendorp PA, Liebregts M, Steggerda RC et al. 2014. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2:630–36
    [Google Scholar]
  58. 58. 
    Sorajja P. 2017. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of balance. J. Am. Coll. Cardiol. 70:489–94
    [Google Scholar]
  59. 59. 
    Sherrid MV, Balaram S, Kim B et al. 2016. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J. Am. Coll. Cardiol. 67:1846–58
    [Google Scholar]
  60. 60. 
    Maron BJ, McKenna WJ, Danielson GK et al. 2003. American College of Cardiology/European Society of Cardiology clinical expert consensus document of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 42:1687–713
    [Google Scholar]
  61. 61. 
    Rowin EJ, Maron BJ, Olivotto I, Maron MS 2017. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc. Imaging 10:1374–86
    [Google Scholar]
  62. 62. 
    Sherrid MV, Shetty A, Winson G et al. 2013. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ. Heart Fail. 6:694–702
    [Google Scholar]
  63. 63. 
    Sherrid MV, Barac I, McKenna WJ et al. 2005. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 45:1251–58
    [Google Scholar]
  64. 64. 
    Olivotto I, Oreziak A, Barriales-Villa R et al. 2020. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759–69
    [Google Scholar]
  65. 65. 
    Saberi S, Cardim N, Yamani M et al. 2021. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 143:606–8
    [Google Scholar]
  66. 66. 
    Maron MS, Rowin EJ, Olivotto I et al. 2016. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 67:1399–409
    [Google Scholar]
  67. 67. 
    Maron MS, Kalsmith BM, Udelson JE et al. 2010. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ. Heart Fail. 3:574–79
    [Google Scholar]
  68. 68. 
    Rowin EJ, Hausvater A, Link MS et al. 2017. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 136:2420–36
    [Google Scholar]
  69. 69. 
    Maron BJ, Olivotto I, Bellone P et al. 2002. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 39:301–7
    [Google Scholar]
  70. 70. 
    Boll G, Rowin EJ, Maron BJ et al. 2020. Efficacy of combined Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 125:120–26
    [Google Scholar]
  71. 71. 
    Carrick RT, Maron MS, Adler A et al. 2021. Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF score. Circ. Arrhythm. Electrophysiol. 14:e009796
    [Google Scholar]
  72. 72. 
    Maurizi N, Michels M, Rowin EJ et al. 2019. Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy. Circulation 139:830–33
    [Google Scholar]
  73. 73. 
    Maron BJ, Roberts WC, Arad M et al. 2009. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301:1253–59
    [Google Scholar]
  74. 74. 
    Shirani J, Aurshiya R, Elshaikh A et al. 2021. Low risk of hypertrophic cardiomyopathy implemented in a non-referral and regional community-based center. Am. J. Cardiol. 142:130–35
    [Google Scholar]
  75. 75. 
    Maron BJ. 2015. Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India. Am. J. Cardiol. 116:332–34
    [Google Scholar]
  76. 76. 
    Rowin EJ, Maron MS, Wells S et al. 2019. Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy. J. Am. Heart Assoc. 8:e012041
    [Google Scholar]
/content/journals/10.1146/annurev-med-042220-021539
Loading
/content/journals/10.1146/annurev-med-042220-021539
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error